Lakefront Biotherapeutics NV (LON:0JXZ)

Market Cap	1.37B -14.4%
Revenue (ttm)	852.94M +259.4%
Net Income	513.70M
EPS	7.77
Shares Out	n/a
PE Ratio	2.67
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	585
Open	22.48
Previous Close	23.32
Day's Range	22.86 - 24.50
52-Week Range	22.38 - 32.70
Beta	0.11
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 10, 2026

About LON:0JXZ

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relaps...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 452
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0JXZ

Financial Performance

In 2025, LON:0JXZ's revenue was 1.11 billion, an increase of 303.50% compared to the previous year's 275.65 million. Earnings were 320.88 million, an increase of 333.15%.

Financial numbers in EUR

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 12, 2026

Data Sources Report a data error